Brian Stevens compensation by year
BAXTER INTERNATIONAL Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $517,471 |
| Bonus | $350,000 |
| Stock awards | $1,142,141 |
| Option awards | $131,756 |
| Non-equity incentive | $344,097 |
| Pension and deferred compensation | $0 |
| All other | $43,836 |
| Total | $2,529,301 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BAXTER INTERNATIONAL INC DEF 14A filed March 25, 2024, accession 0001193125-24-075975, and prior-year filings.
How this page was built: the BAXTER INTERNATIONAL INC filed document, accession 0001193125-24-075975. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 13,994 | $541,008 | — |
| RSU | 9,252 | $357,664 | — |
| RSU | 6,885 | $266,178 | — |
| RSU | 5,994 | $231,710 | — |
| PSU | 3,443 | $133,089 | — |
| RSU | 2,467 | $95,372 | — |
| PSU | 925 | $35,774 | — |
| PSU | 816 | $31,553 | — |
| RSU | 614 | $23,744 | — |
| Option | 5,808 | — | $77.15 |
| Option | 5,513 | — | $85.23 |
| Option | 14,072 | — | $39.06 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BAXTER INTERNATIONAL INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
BAXTER INTERNATIONAL’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| José Almeida | Chair of the Board, President and Chief Executive Officer | $13,786,671 |
| Christopher Toth | Executive Vice President and Group President, Kidney Care | $9,640,315 |
| Cristiano Franzi | Former Senior Vice President and President, EMEA | $6,884,907 |
| Joel Grade | Executive Vice President and Chief Financial Officer | $4,876,222 |
| Heather Knight | Executive Vice President and Group President, Medical Products & Therapies | $4,860,243 |
| Alok Sonig | Executive Vice President and Group President, Pharmaceuticals | $3,866,033 |
| James Saccaro | Former Executive Vice President and Chief Financial Officer | $3,705,753 |
| Brian Stevens · this page | Senior Vice President, Chief Accounting Officer & Controller and Former Interim Chief Financial Officer | $2,529,301 |
The full BAXTER INTERNATIONAL compensation record
free company briefThis page is one person within BAXTER INTERNATIONAL's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BAXTER INTERNATIONAL proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BAXTER INTERNATIONAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.